Who is on it, and how far along Every drug ChEMBL records acting on P, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved5 Tenofovir disoproxil Tenofovir disoproxil SponsorGilead Sciences ModalitySmall molecule ActionInhibitor Open trials160 Lamivudine Lamivudine SponsorViiV Healthcare ModalitySmall molecule ActionInhibitor Open trials64 Telbivudine Telbivudine SponsorNovartis Pharmaceuticals ModalitySmall molecule ActionInhibitor Open trials1 Adefovir dipivoxil Adefovir dipivoxil SponsorGilead Sciences ModalitySmall molecule ActionInhibitor Open trials0 Entecavir anhydrous Entecavir anhydrous SponsorJohnson & Johnson ModalitySmall molecule ActionInhibitor Open trials0 Phase 33 Adefovir Adefovir SponsorJiangsu Hansoh Pharmaceutical ModalitySmall molecule ActionInhibitor Open trials1 Pradefovir Pradefovir SponsorBausch Health ModalitySmall molecule ActionInhibitor Open trials1 Tenofovir anhydrous Tenofovir anhydrous SponsorHepatera Ltd. ModalitySmall molecule ActionInhibitor Open trials0 Phase 22 Elvucitabine Elvucitabine SponsorAstraZeneca Pharmaceuticals ModalitySmall molecule ActionInhibitor Open trials0 LB80380 LB80380 SponsorLG Life Sciences ModalitySmall molecule ActionInhibitor Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. All act as: DNA polymerase/reverse transcriptase inhibitor. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 18 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Phase Ib Clinical Trial of ACT201 Injection in Participants With Treatment-Naïve Chronic Hepatitis B Tenofovir disoproxil Phase 1 Not yet recruiting Xiamen Amoytop Biotech Co., Ltd. Nov 18, 2026 People With Active Viremia Treated With Lenacapavir and Long-Acting Cabotegravir for Effectiveness Tenofovir disoproxil Phase 1 Not yet recruiting National Institute of Allergy and Infectious Diseases (NIAID) Nov 16, 2026 Cohort of Women Living With HIV-1 and Receiving Bictegravir/Emtricitabine/Tenofovir Alafenamide Tenofovir disoproxil — Recruiting Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida Nov 6, 2026 Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIV Tenofovir disoproxil Phase 4 Not yet recruiting Gilead Sciences Nov 2, 2026 Starting HIV Prevention Medicine (PrEP) During an Emergency Department Visit With a Peer Navigator Tenofovir disoproxil Phase 4 Not yet recruiting University of South Florida Oct 28, 2026 Effects of Switch to Doravirine/Islatravir vs. Continued Antiretroviral Therapy on Biomarkers of Aging Among Virologically Suppressed People With HIV Lamivudine, Tenofovir disoproxil Phase 2 Not yet recruiting The University of Texas Health Science Center, Houston Oct 13, 2026 Study on Retention in Care and on Clinical Chracteristics of HIV-infected Women Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIKWO). Tenofovir disoproxil — Not yet recruiting Ente Ospedaliero Ospedali Galliera Oct 6, 2026 Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels Tenofovir disoproxil Phase 2 Recruiting Gilead Sciences Sep 25, 2026 A Phase 2b Study Evaluating VH4011499 Capsid Inhibitor Long-Acting Injectable Plus Cabotegravir in Treatment Naïve Adults (CINERGY) Lamivudine Phase 2 Not yet recruiting ViiV Healthcare Sep 11, 2026 An Adaptive Platform Trial for Evaluation of Novel Treatment Regimens in Children and Adolescents With HIV in Africa Lamivudine Phase 3 Not yet recruiting University College, London Aug 28, 2026 Effectiveness and Safety of Darunavir/Cobicistat Plus Lamivudine Compared With Darunavir/Cobicistat Plus Tenofovir Alafenamide/Emtricitabine in Virologically Suppressed People Living With HIV at 24 and 48 Weeks of Follow-up Lamivudine Phase 4 Recruiting Instituto Mexicano del Seguro Social Jul 1, 2026 Sleep Outcomes and Multidimensional Sleep Assessment - a Randomized Trial of Dolutegravir- vs Doravirine-based Antiretroviral Therapy in People Living With HIV Lamivudine Phase 4 Not yet recruiting University of Witwatersrand, South Africa Jun 29, 2026 Lamivudine as a Novel Clinical Effort for Rett Syndrome Lamivudine Phase 2 Enrolling by invitation Maria Denise Fernandes Carvalho de Andrade Jun 10, 2026 Comparative Trial Between Ainuovirine(ANV)/Lamivudine(3TC)/Tenofovir(TDF) and Efavirenz(EFV)/Lamivudine/Tenofovir Regimens Lamivudine Phase 4 Not yet recruiting Shanghai Public Health Clinical Center Jun 8, 2026 Dolutegravir/Lamivudine in Treatment-Naïve Pregnant Women Lamivudine Phase 4 Recruiting Fundación Huésped Jun 1, 2026 A Real-World Study on the Efficacy and Safety of Pradefovir Mesylate Tablets in the Treatment of Chronic Hepatitis B Pradefovir — Active, not recruiting Juan Li Apr 29, 2026 Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study) Telbivudine — Recruiting Yaşar Bayındır, MD Mar 9, 2026 Halting Nucleoside Analogues in Chronic Hepatitis B Adefovir Not applicable Active, not recruiting Seng Gee Lim Sep 25, 2019
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2362994 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-21. ChEMBL and Open Targets